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Continuous periaortic infusion improves
doxycycline efficacy in experimental aortic
aneurysms
Eiketsu Sho, PhD,a,b Jack Chu, PhD,c Mien Sho, MD,a,b Brian Fernandes, PhD,c Diane Judd, BS,c
Prema Ganesan, BS,c Hideo Kimura, PhD,a,b and Ronald L. Dalman, MD,a,b Palo Alto and Santa Rosa,
Calif
Objective: We created a novel continuous infusion system to evaluate the efficacy of juxta-aortic doxycycline delivery as a
transitional step toward developing hybrid drug/device treatment strategies for abdominal aortic aneurysm (AAA)
disease.
Methods: Controlled comparison of treatment outcomes was studied in animal models with molecular and morphologic
tissue analysis in a collaboration between university and corporate research laboratories. Rat AAAs were created via
porcine pancreatic elastase (PPE) infusion and grouped and analyzed by subsequent treatment status (either doxycycline
in vehicle or vehicle alone) and drug delivery method (continuous infusion via periaortic delivery system [PDS] or
twice-daily subcutaneous injection). The main outcome measures were AAA diameter via direct measurement, medial
elastin lamellar preservation via light microscopy, mural smooth muscle cell (SMC) proliferation and SMC and
macrophage density via immunostaining and counting, expression of matrix metalloproteinases 2, 9, and 14 and tissue
inhibitors of metalloproteinases 1 and 2 via real-time reverse transcriptase–polymerase chain reaction, and enzymatic
activity via substrate zymography. Serum drug levels were analyzed via liquid chromatography/mass spectroscopy.
Results: PDS (1.5 mg/kg/day) and subcutaneous (60 mg/kg/day) delivery methods caused comparable reductions in
AAA diameter during the period of 14 days after PPE infusion. PDS rats gained more weight during the postoperative
period (P < .001), possibly as a result of reduced serum drug levels and systemic toxicity. Doxycycline treatment reduced
AAA macrophage infiltration and SMC proliferation significantly. Despite reduced diameter, circumferential elastic
lamellar preservation was not apparent in doxycycline-treated AAAs.
Conclusions: Continuous periaortic infusion lowers the effective doxycycline dose for experimental AAA limitation.
Alternative biologic inhibition strategies might also be amenable to direct intra-aortic or juxta-aortic delivery. Periaortic
infusion might improve the clinical outcome of minimally invasive AAA treatment strategies. (J Vasc Surg 2004;39:
1312-21.)
Clinical Relevance: Aneurysm remodeling may continue after successful endovascular AAA exclusion. Continued
proteolytic activity within the aneurysm wall potentiates late graft migration and failure. The doxycycline infusion system
developed in these experiments may serve as a prototype for adjuvant treatment modalities that complement endovascular
AAA exclusion. Local delivery of doxycycline or other agents active in AAA disease, either continuously or at selected
intervals after graft implantation, may stabilize the wall and aid in maintaining aneurysm exclusion. Alternative delivery
methods could include passive diffusion from either the graft material itself or treatment reservoirs incorporated into
endografts. Given the recognized limitations of current technologies, adjuvant biologic therapies have the potential to
improve long-term patient outcome significantly after endovascular exclusion.Abdominal aortic aneurysm (AAA) disease is a chronic
condition characterized by progressive aortic medial vascu-
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degradation, impaired aortic integrity, and ultimate rup-
ture. Although the initiating influences of AAA disease
remain poorly characterized, aneurysmal dilatation is pri-
marily attributed to progressive proteolytic depletion of
medial and adventitial elastin.1-3 Elastolytic proteinases are
up-regulated in AAA tissue, including matrix metallopro-
teinases (MMPs)–2 and 9, and expressed principally by
infiltrating macrophages, vascular smooth muscle cells
(SMCs), and endothelial cells.4-6 The co-occurrence of
elastolytic activity, elastin degradation, and aneurysm en-
largement has led to the observation that pharmacologic
inhibition of MMP activity might retard aortic wall matrix
degradation and aneurysm growth in patients with small
AAAs or those not amenable to surgical repair.
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is doxycycline, a member of tetracycline antibiotic family.7
Petrinec et al8 first demonstrated that doxycycline therapy
inhibited MMP-9 activity, preserved elastic lamellar struc-
ture, and reduced enlargement of experimental AAAs.
More recently, the efficacy of oral doxycycline therapy in
preventing small AAA expansion and modifying serum
MMP levels has been tested in small-scale clinical trials.9-11
AAA limitation in small mammalian models has generally
required doxycycline dosages nearly 10-fold higher (30-60
mg/kg/day) than the typical human antimicrobial dose
range (2-4 mg/kg/day). Clinical efficacy in limiting AAA
progression with doxycycline in the antimicrobial dose
range remains unconfirmed. To date, no attempt has been
made to optimize aortic MMP inhibition and to limit
systemic drug levels by delivering doxycycline directly onto
the aneurysm.
If continuous juxta-aortic or intra-aortic doxycycline
therapy does limit MMP activity and AAA progression with
lower systemic doxycycline levels, this technique might
prove to be an effective adjunctive therapy for endovascular
AAA repair (EVR). Limiting mural proteolytic activity in or
around the aneurysm sac after endovascular exclusion
might significantly reduce late remodeling, loss of graft
fixation, and distal migration. In addition to doxycycline-
mediated MMP inhibition, a wide range of pharmacologic
strategies has been proposed to modify or to stabilize AAA
progression.12-14 Adjunctive EVR drug delivery systems
could potentially deliver multiple agents concurrently or in
sequence in the months or years after device placement,
guided by ongoing image- or sensor-guided analysis of
aneurysm morphology, diameter, or sac endotension.
We developed a periaortic drug delivery system (PDS)
for the rat porcine pancreatic elastase infusion (PPE) AAA
model to compare the efficacy of continuous juxta-aortic
Fig 1. PDS. The PE-10 tubing is placed adjacent to the a
with polyvinyl alcohol foam, and tunneled across the a
doxycycline solution or vehicle alone (representative phoinfusion versus traditional twice-daily subcutaneous doxy-
cycline injections in limiting aneurysm progression as the
first step in the potential future development of hybrid
drug/device AAA treatment strategies.
MATERIAL AND METHODS
AAA model. Male Sprague-Dawley rats (250-350 g)
underwent aortic PPE infusion as previously de-
scribed.15,16 Briefly, the infrarenal aorta was isolated, mo-
bilized, and controlled via laparotomy. A polyethylene
catheter (PE-10) was advanced into the 15-mm long distal
aortic segment from the right femoral artery. One milliliter
of normal saline containing 7 m type I PPE (E-1250;
Sigma Chemical, St Louis, Mo) was infused via syringe
pump into the controlled segment during a 1-hour period.
After infusion the catheter and any residual elastase were
withdrawn, and inline aortic flow was restored. All experi-
mental surgical procedures were approved by the Institu-
tional Animal Care and Use Committee of the Veterans
Affairs Palo Alto Health Care System and were conducted
in compliance with Stanford University Administrative
Panel on Laboratory Animal Care Guidelines, including
but not limited to those related to Rodent Survival Surgery
(http://labanimals.stanford.edu/guidelines/rodent_surg.
html) and Endpoint Monitoring and Humane Termination
((http://labanimals.stanford.edu/guidelines/endpoint.html)
(both updated October 1998).
PDS. The PDS was constructed in the following man-
ner. After the PPE infusion was complete and the aortic
catheter was withdrawn, a second PE-10 tube was secured
to the anterior aortic surface with a 1-mm thick sheet of
circumferential periaortic porous polyvinyl alcohol foam
(2.5 cm2 total area). The foam was positioned to capture
doxycycline infused through the PE-10 tubing and to
maintain relatively high periaortic concentration gradients
mmediately after intraluminal elastase infusion, wrapped
inal wall to connect with a reservoir containing either
aph).orta i
bdom
togr
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other end of the PE-10 tubing was tunneled into a lateral
subcutaneous pocket through the abdominal wall. A 2-mL
osmotic pump (Model 2ML2; Azlet Osmotic Pumps, Cu-
pertino, Calif) was secured in the pocket and connected to
the tubing. The osmotic pumps were preloaded with either
doxycycline in saline or saline alone as described below.
Study groups. AAA groups were defined on the basis
of treatment modality, either continuous retroperitoneal
infusion via the PDS or subcutaneous injection (SC). PDS
rats were treated with either doxycycline in saline (PDS-
DOX subgroup, n  9; 5 mg/mL infused at 5 L/h
delivering 1.5 mg/kg/day) or control saline solution
(PDS-CON subgroup, n  9; 5 L/h). SC rats were
treated with twice-daily injections of either doxycycline in
saline (SC-DOX subgroup, n  9; 15 mg/kg in 0.5 mL)
for a total doxycycline dose of 30 mg/kg/day or saline
alone (SC-CON subgroup, n 9; 0.5 mL). Treatment was
continued for 14 days after PPE infusion. Three additional
AAA rats were created for molecular analysis and sacrificed
at 14 days without any postoperative infusions or injec-
tions. Rats were sacrificed by intentional anesthetic over-
dose. Aortic external diameter was the primary index of
aneurysm progression, measured in situ before and after
PPE infusion and immediately before sacrifice by using
electronic microcalipers. Measurements were consistently
obtained at the point of maximum transverse diameter.
Observers were blinded to treatment status at the time of
measurement.
Serum drug concentration. One milliliter of rat tail-
vein blood was drawn on days 2, 4, 7, and 14 after PPE
infusion/treatment initiation and saved in 10% ethyl-
enediaminetetraacetic acid. Serum doxycycline concentra-
tion was determined in all groups at all time points via
liquid chromatography/mass spectroscopy (PPD Discov-
ery, Morrisville, NC).
Metalloproteinase and inhibitor expression. Before
sacrifice the aneurysmal aortic segment was dissected free of
surrounding retroperitoneal tissue via repeat laparotomy.
After diameter measurement and sacrifice, aneurysms were
harvested, snap frozen in liquid nitrogen, and stored at
80°C. Real-time reverse transcriptase–polymerase chain
reaction (PCR) was performed with the GeneAmp 7700
sequence detection system (Applied Biosystems, Foster
City, Calif).15 High quality total RNA was extracted by
using TRIzol reagent (Gibco BRL, Rockville, Md) and
Table I. Oligonucleotides used for real time reverse transc
GeneBank
No. Forward primer
MMP-2 NM_031054 5-TGCTGGAGAACCTGAAGTGT-
MMP-9 NM_031055 5-TGGCTCTAGGCTACAGCTTTG
MMP-14 NM_031056 5-GCCATGCAAAGGTTCTATGGT
TIMP-1 U06179 5-GGCCTCTGGCATCCTCTTG-3
TIMP-2 NM_021989 5-GCTGGACGTTGGAGGAAAGA-
-actin NM_031144 5-GGGAAATCGTGCGTGACAT-3used to generate cDNA for oligo-deoxythymidine oligode-
oxynucleotide primer (T12-18) by using the Superscript II
reverse transcriptase system (Invitrogen, Carlsbad, Calif).
The following primers were designed by using Primer
Express software (Applied Biosystems) and synthesized:
MMP-2, MMP-9, MMP-14, tissue inhibitor of metallo-
proteinases (TIMP)-1, and TIMP-2 (Table I). Equal
amounts of cDNA were used in duplicate and amplified
with the SYBR Green I Master Mix System (Applied Bio-
systems). PCR was performed after thermal activation for
10 minutes at 95°C followed by 40 cycles of warming for
15 seconds at 95°C and annealing/extension for 1 minute
at 60°C. Amplification efficiencies were validated and nor-
malized against -actin. Correct PCR product size was
confirmed by electrophoresis through 2% agarose gel with
ethidium bromide.
Gelatinase activity. Aortic proteins were extracted as
previously described.16 For detection of MMP-2 and
MMP-9 activity, equal amounts of samples standardized
for protein concentration (20 g) were loaded on each
lane and run in parallel in 10% sodium dodecylsulfate–
polyacrylamide gel electrophoresis gels containing 1% gel-
atin (Invitrogen). The molecular sizes of gelatinolytic ac-
tivities were determined with prestained protein
standards (Invitrogen). Gels were washed with Triton
X-100 (2.5%) and then incubated overnight (37°C) in
developing buffer (50 mmol/L Tris Base and 10
mmol/L CaCl2). Zones of lysis were visualized after staining
the gels with 0.5% Coomassie blue R-250. Densitometric
analysis of lytic bands for MMP-2 and MMP-9 was per-
formed by public domain software NIH Image version
1.61 (http://rsb.info.nih.gov/nih-image/index.html).
Cellular proliferation and inflammatory cell infil-
tration. To investigate intrinsic aortic cell proliferation,
selected rats in all groups received an intraperitoneal ad-
ministration of bromodeoxyuridine (BrdU) at 50 mg/kg
(Sigma Chemical, St. Louis, Mo) in physiologic saline
solution (5 mg/mL) 1 hour before sacrifice to “pulse label”
cells in DNA synthesis (S) phase. After sacrifice these rats
were pressure perfusion fixed with 4% paraformaldehyde
solution in 0.1 mol/L phosphate buffer (pH, 7.4; 20°C)
via the left ventricle for 30 minutes at an intra-arterial
pressure of 100 mm Hg. Following the immunohisto-
chemical staining protocol, the tissue sections were pre-
pared and incubated with anti-BrdU mouse monoclonal
antibody (Becton Dickinson) at 1:50 dilution in 0.1%
se-polymerase chain reaction
Reverse primer product (base pair)
5-AGATTGATGCCGTGTACGAG-3 101
5-CGACACCAAACTGGATGACAA-3 101
5-CGCCTCATAGCCTTCATCGT-3 71
5-CCAGGTCCGAGTTGCAGAAA-3 101
5-TGTCCCAGGGCACAATAAAGT-3 101
5-CAGGAGGAGCAATGATCTT-3 101ripta
3
-3
T-3
3
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for 1 hour. After washing, sections were incubated 1 hour
with a biotinylated anti-mouse immunoglobulin G (KPL
Lab Inc, Gaithersburg, Md) at room temperature following
the ABC method according to the manufacturer’s protocol
and counterstained with hematoxylin. Medial SMC prolif-
eration was defined as all BrdU-positive SMCs/section (2
sections/case). All sections were counted twice and aver-
aged for a final value.
Mouse anti-rat ED-1 monoclonal antibody was ob-
tained from Serotec, Inc (Raleigh, NC). Biotinylated anti-
mouse secondary antibody and ABC kits were both ob-
tained from Vector Laboratories, Inc (Burlingame, Calif).
Tissue sections were prepared for immunohistochemical
staining in the following manner; after blocking nonspecific
binding with horse serum (1:200 diluted in PBS) for 30
minutes at room temperature and rinsing with PBS, sec-
tions were incubated with an antigen-specific primary anti-
body followed by biotinylated second antibody according
to the manufacturer’s protocol. The sections were counter-
stained with hematoxylin and examined via light micros-
copy. Medial macrophage infiltration was determined via
cell counting throughout the entire media (2 sections/rat)
as ED-1 positive cells/cross section. Adventitial macro-
phage infiltration was determined on the entire cross sec-
tion (ED-1 positive cells/sections). All sections were
counted twice and averaged for a final value.
Statistical analysis. All data were expressed as mean
standard deviation. Statistical analysis was performed by
using the one-way analysis of variance for non-normally
distributed populations with the Bonferroni-Dunn correc-
tion for multiple comparisons. Differences were considered
statistically significant at P  .05.
Table II. Weight gain following PPE infusion as a functio
BW (% increase)
Day 0 Day
PDS-DOX 343.4  17.1 416.3  14.1 (
PDS-CON 338.5  9.4 395.3  8.7 (1
SC-DOX 326.1  9.0 365.1  18.3 (
SC-CON 342.1  9.4 412.3  12.8 (
BW, Body weight (gm); SP, total solution in pump (mL); PDS-DOX, p
subcutaneous doxycycline injections; SC-CON, subcutaneous saline injectio
*P  .001 vs other groups.
Table III. Influence of delivery method on serum doxycyc
Day 2 Day 4
PDS-DOX 17.5  3.8 17.4  4.3
SC-DOX 725.6  242* 776.0  19
PDS-DOX, Retroperitoneal infusion system; SC-DOX, subcutaneous inject
*P  .00001 vs PDS-DOX group.
†P  .001 vs day 2 and day 7 within SC-DOX group.RESULTS
The PPE infusion dose and dwell time were reduced in
these experiments to minimize artifactual influences related
to infusion pressure and aortic ischemia and to emphasize
inflammation as the primary etiologic agent for aneurysmal
degeneration. Despite these protocol modifications, AAAs
were produced in adequate numbers in all groups; 89% of
the rats (32/36) developed at least 60% diameter enlarge-
ment between the end of the infusion and sacrifice. One rat
in each of the four groups failed to reach this threshold,
leaving eight rats per group for further analysis.
In both the PDS-DOX and PDS-CON groups greater
than 85% of the pump reservoir was delivered to the peri-
aortic foam collar during the 14-day postoperative period
(Table II). Despite 60-fold lower serum doxycycline levels
(Table III; day 14, P  .001) in PDS versus SC-DOX rats,
the degree of AAA diameter reduction achieved versus
suitable controls was comparable between the two groups
(P  not significant; Table IV). SC-DOX rats also gained
significantly less weight during the 14-day treatment period
than PDS-DOX rats (P  .01; Table II). Serum doxycy-
cline levels also varied more widely as a function of time in
SC-DOX versus PDS-DOX rats (Table III).
Histologically, aortic endothelial cell and medial SMC
populations were reduced immediately after PPE infusion
(90% and 43%, respectively). The modified infusion proto-
col did limit initial postinfusion internal elastic lamellar
degeneration compared to previous experiments15 (Fig 2),
but at 14 days the characteristic transmural monomorpho-
nuclear and polymorphonuclear inflammatory cell infil-
trate, near-complete elastin dissolution, and progressive
diameter enlargement associated with PPE infusion were
uniformly present. Regenerating and possibly proliferating
endothelial cells and SMCs were present along the inner
DOX treatment status
SP (% delivered)
Day 0 Day 14
 3.2) 2.0 0.3  0.03 (84.9  1.5)
3.6) 2.0 0.3  0.05 (85.2  2.4)
 3.8)* N/A N/A
 4.7) N/A N/A
tic doxycycline infusion; PDS-CON, periaortic saline infusion; SC-DOX,
concentrations (ng/mL)
Day 7 Day 14
16.4  4.6 21.1  8.5
1359.7  137.1*† 1243.7  187.9*†n of
14
20.0
7.3 
11.9
20.6
eriaor
ns.line
2.1*
ions.
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to a lesser degree than that previously reported to occur
under high aortic flow conditions.16 Well-differentiated
SMCs in this region produced and were surrounded by
newly synthesized elastic fibers as confirmed by Masson
trichrome staining (Fig 3).
Table IV. Influence of doxycycline treatment status/meth
Pre-PPE Post-PPE (increase
PDS-CON 1.73  0.04 2.09  0.04 (21.1 
PDS-DOX 1.71  0.03 2.11  0.03 (24.3 
SC-CON 1.74  0.02 2.12  0.03 (21.8 
SC-DOX 1.67  0.08 2.07  0.06 (23.6 
Pre-PPE, Aortic diameter before PPE infusion (mm); Post-PPE, diameter i
infusion (mm).
*Percent increase vs Post-PPE diameter.
†Diameter reduction vs saline treatment alone.
‡P  .019 vs PDS-CON group.
§P  .19 (not significant) vs PDS-CON group.
P  .025 vs SC-CON group.
Fig 2. Infusion-related endothelial, smooth muscle, and
(i) Hematoxylin-eosin stain; (ii) aortic elastin autofluore
Fig 3. Effect of doxycycline treatment status on elastin p
reduced with either twice-daily subcutaneous injections
(PDS-DOX, 1.5 mg/kg/day) doxycycline therapy. SC
lamellar attenuation as a function of doxycycline treatme
luminal side of the degenerating media surrounded by n
elastin Masson trichrome stain).In addition to limiting AAA enlargement, doxycycline
treatment status influenced aortic cellularity. Macrophage
transmural infiltration was reduced in the medial layer in
both the PDS-DOX and SC-DOX groups as compared to
PDS-CON and SC-CON groups (P  .01, Fig 4). No
difference in macrophage density was noted as a function of
n AAA diameter
Death (increase %)* AD reduction †
4.52  0.52 (116.8  25.5)
3.84  0.51 (80.8  24.1)‡ 35.2%
5.25  1.14 (148.0  53.9)§
3.86  0.72 (86.2  34.2) 45.9%
iately after PPE infusion (day 0, mm); Death, diameter 14 days after PPE
ellar injury as a function of PPE dose and infusion time.
e, both original magnification 400.
vation. AAA diameter (i, original magnification 4) was
OX, 60 mg/kg/day) or continuous periaortic infusion
N, AAA treated with vehicle alone. ii, Medial elastic
tus (arrowheads). Proliferating SMCs are present on the
synthesized elastin fibers (original magnification 400;od o
%)
3.0)
1.3)
2.4)
6.2)
mmedlam
scencreser
(SC-D
-CO
nt sta
ewly
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not significant). BrdU pulse-labeling showed reduced SMC
proliferation and regeneration in doxycycline-treated
rats (P  .05) (Fig 5), suggesting that doxycycline
limited medial SMC regeneration after aneurysm forma-
tion. No differences in aortic elastin preservation were
noted between either DOX group or control AAAs.
Increased expression of mRNA for MMP-2, -9, and -14
and TIMP-1 and -2 were noted in all AAA groups
compared to control aorta. Doxycycline treatment status
affected only MMP-9 expression; message for MMP-2
and -14 and TIMP-1 and -2 was similar to that present in
AAAs treated with saline alone (Fig 6). MMP-9 expres-
sion was lower in SC-DOX than PDS-DOX rats (P 
.015), perhaps because of the higher serum levels asso-
ciated with subcutaneous injection. Gelatin zymography
of aortic extracts showed lytic bands at 72 and 62 kd in all
AAA groups, consistent with proteolytic activity of the
pro- and active forms, respectively, of MMP-2. Signifi-
cant gelatinolysis was also noted at 92 and 86 kd, indi-
cating increased pro- and active MMP-9 activity. Activity
of both MMP-9 isoforms was reduced in doxycycline-
treated rats. MMP-2 activity, however, was apparently
Fig 4. Effect of doxycycline treatment status on transmu
treatment; (iii) index of macrophage medial infiltration. B
media. *P  .01 vs doxycycline treatment group. Originnot influenced by doxycycline treatment (Fig 6). PDS-
DOX treatment resulted in reduced pro–MMP-9 activity
compared with SC-DOX–treated rats (P  .002).
DISCUSSION
This study demonstrated the feasibility, initial effective-
ness, and potential advantages of a novel drug delivery
system for experimental aortic aneurysm therapy. Low dose
doxycycline delivered continuously to the periaortic retro-
peritoneal space attenuated aortic expansion, reduced mac-
rophage infiltration, and limited SMC proliferation. These
effects were achieved with dramatic reductions in serum
drug levels compared to standard systemic doxycycline
dosing protocols.
The PDS method evolved from previously tested pro-
totypes that used drug-eluting fabric patches or viscous gels
to deliver doxycycline to the periaortic space. PDS proved
least likely among these methods to precipitate premature
rupture or artifactually to limit diameter enlargement. Any
local infusion method might influence AAA progression, if
only as a consequence of the extra dissection required for
placement. Although polyvinyl alcohol itself is not biolog-
ically inert, in this experiment the presence of the foam
acrophage density. (i) Doxycycline treatment; (ii) saline
nuclei, ED-1 positive cells; CSA, cross-sectional area of
gnification 400.ral m
rown
al ma
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IV).
Doxycycline inhibits proteolytic activity via direct en-
zyme inhibition, as well as down-regulation of MMP-9
gene transcription.17 In addition to these direct effects,
doxycycline also reduces interleukin-1 levels,18 inhibits
murine macrophage nitric oxide synthase activity,19 in-
duces macrophage apoptosis,20 and reduces reactive oxy-
gen species in vitro,21 activities that might also influence
aortic inflammation, diameter enlargement, and wall frag-
mentation in AAA disease. In contrast with reports from
earlier studies,8,22,23 the medial elastic lamellae were not
well preserved in either doxycycline treatment group in this
experiment. This apparent inconsistency might reflect lim-
itations inherent to the model. These aneurysms demon-
strate significant circumferential and longitudinal hetero-
geneity in the degree of aortic inflammation, elastolysis,
and mural thrombus formation present after PPE infusion.
As a result, well-formed lamellae are clearly seen in isolated
sections in some aneurysms (as demonstrated in the low
power sections in Fig 3, as an example), irrespective of
doxycycline treatment status. We also used lower PPE
Fig 5. Effect of doxycycline treatment status on aortic
actively remodeling aortic wall after PPE infusion. i, AA
(original magnification 400); iii, index of BrdU-labele
 .01 vs doxycycline treatment group.doses and shorter infusion times than those reported in
previous experiments, changes that might limit artifactual
lamellar dissolution during the aneurysm initiation phase.
Taken as a whole, however, no consistent circumferential
evidence of lamellar preservation attributable to treatment
status is present in doxycycline-treated AAAs.
If the elastic lamellae are not preserved, what alternative
mechanisms account for doxycycline-mediated AAA sup-
pression? We noted a consistent reduction in transmural
macrophage density in doxycycline-treated AAAs com-
pared to control, findings at odds with those reported by
Petrinec et al8 with a similar model but consistent with in
vitro observations regarding the ability of tetracycline-class
drugs to induce macrophage apoptosis. Reduced macro-
phage infiltration has also been associated with reduced
experimental AAA progression under high flow aortic con-
ditions,24 underscoring the important role that inflamma-
tion plays in aneurysmal degeneration. Relative adventitial
collagen retention might also account for some degree of
diameter reduction present in doxycycline-treated AAAs.
In addition to elastolysis, MMP-2 and -9 also have enzy-
matic activity against arterial collagens types I and III, and
proliferation. Arrows, BrdU-labeled SMC nuclei in the
er doxycycline treatment; ii, AAA after saline treatment
Cs in AAA wall. CSA, Cross-sectional area of media; *PSMC
A aft
d SM
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cally linked to elastin rather than collagen depletion,25
relative adventitial collagen retention might also account
for some degree of the diameter reduction evident in the
doxycycline-treated rats. Confirmation of this hypothesis
will require quantification of AAA collagen and elastin
content in subsequent experiments.
Clinical trials with oral doxycycline therapy to retard
small AAA growth have been reported, are planned, or are
already underway.8,26,27 Adjunctive doxycycline might also
prove effective in limiting aortic remodeling and subse-
quent device migration after endovascular AAA exclu-
sion.28 To date, oral doxycycline doses used in human trials
have been far lower than those shown to be effective in
experimental models (Table V). Even at these lower dos-
Fig 6. MMP gene expression and activity in AAA tissue
reduced AAA MMP-9 gene expression in PDS-DOX gro
and -14 or TIMP-1 and -2. Gelatin gel zymography dem
after doxycycline treatment (C-F). The PDS method was
MMP-2 activity was not affected by doxycycline treatme
(MW) of MMP-2 and MMP-9 were quantified by den
PDS-DOX group.ages, however, doxycycline use might precipitate serious
side effects,9 potentially limiting long-term therapeutic
utility. Continuous periaortic retroperitoneal infusion sub-
stantially reduces overall dose, reduces potentially dose-
related systemic side effects (such as reduced weight gain in
rodent models), and minimizes serum level variability while
maintaining therapeutic efficacy in experimental AAA. Con-
tinuous delivery might also improve therapeutic compliance
via utilization of periodic dosing and reservoir capabilities
similar to those pioneered by continuous insulin infusion
systems in diabetic patients. If proven significant and repro-
ducible in the clinical setting, these advantages might dramat-
ically improve the therapeutic index and ultimate clinical effi-
cacy of doxycycline or other tetracycline derivatives as
adjunctive or stand-alone therapy for AAA suppression.
or without doxycycline treatment. Doxycycline therapy
) and SC-DOX group (B), but it did not affect MMP-2
ated reduced activity of pro- and active forms of MMP-9
effective in this regard than subcutaneous injection (G).
ytic bands corresponding to apparent molecular weight
etry. *P  .01 vs doxycycline treatment; †P  .05 vswith
up (A
onstr
more
nt. L
sitom
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June 20041320 Sho et alAlthough effective in short-term rodent models, the
long-term clinical utility of doxycycline in human AAA
disease treatment remains unknown. Although MMP inhi-
bition might limit destructive matrix remodeling, MMP
activity is also crucial for SMC proliferation and migration,
potentially critical compensatory responses in AAA disease.
SMC depletion is a prominent feature of human AAA
disease, and MMP-9–deficient mice29 and doxycycline-
treated rats (30 gm/kg/day)30 demonstrate reduced aortic
SMC proliferation and migration after aortic injury. In our
experiments doxycycline-treated rats also demonstrated re-
duced SMC proliferation, although the balance of doxycy-
cline therapy remained antianeurysmal as indicated by re-
duced aneurysm diameter. In human disease, AAA
recognition and treatment begin years or decades after
disease onset after extensive cellular depletion and matrix
degeneration. To replicate the human condition more ac-
curately, experimental models should initiate therapy at late
intervals after PPE infusion, a staggered approach yet to be
tested in any model and a significant goal for further
investigations. Regardless of the results reported in small
mammalian models, the ultimate consequences of pro-
longed doxycycline administration for human AAA inhibi-
tion will need to be determined in valid clinical trials.
Although doxycycline was chosen for these experi-
ments, continuous periaortic infusion is likely to offer dis-
tinct advantages over oral or parenteral administration of
any suppressive agent in regard to local tissue concentra-
tions, systemic effects, and toxicity indexes. A number of
alternative drugs, such as angiotensin-converting enzyme
and 3-hydroxy-3-methylglutaryl coenzyme A reductase in-
hibitors (statins), limit experimental AAA progression and
have great potential utility for human AAA therapy.12-14
Synchronous or staged infusions of multiple agents at a
variety of time points might ultimately prove most effective
for aneurysm suppression, either for preclinical lesions
identified by screening or as adjunctive therapy after EVR
exclusion.
Table V. Summary of doxycycline dosages reported effecti
Investigator Animal model Local deliver
Thompson RW
(1996)8 Rat-PPE N/A
(1998)23 Rat-PPE N/A
(2000)31 Rat-PPE N/A
(2000)32 Mouse-PPE N/A
Baxter BT
(2002)9 Mouse-CaCl2 N/A
Daugherty A
(2003)13 Mouse-Ang II N/A
Present study
(2003) Rat-PPE 1.5 mg/kg/da
For the present series the diameter differences were calculated from preoper
to conform with methods used in other. All measurements at 14 days excep
SC, Doxycycline subcutaneous injection; PO, doxycycline dissolved in drink
*Reduction in doxycycline-treated group vs control group; the average degre
the preinfusion and final diameter.In summary, this study demonstrates the utility of
continuous periaortic infusion as an alternative method of
achieving doxycycline-induced MMP-9 inhibition and an-
eurysm progression in experimental AAAs. Reduced serum
doxycycline levels associated with this delivery method
might limit systemic side effects while maintaining thera-
peutic efficacy. The efficacy of doxycycline as a clinical AAA
suppression agent awaits confirmation by ongoing and
future clinical trials. Studies to further define the role of
medial SMC apoptosis, proliferation, and differentiation in
aortic aneurysms might lead to additional potentially com-
plementary adjunctive therapies for this serious and life-
threatening disease.
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